On 26 June 2019, Germany was included in the mutual recognition agreement between the European Union and the US Food and Drug Administration (FDA). The FDA has thus confirmed the ability of this additional EU Member State to carry out GMP (Good Manufacturing Practice) inspections at a level equivalent to that of the United States. The agreement mutually recognises inspections of production sites for medicinal products for human use carried out in the different areas. *Restrictions: Capacity rules apply to routine surveillance inspections. These agreements benefit regulators by reducing double inspections in any other area, allowing for a greater focus on higher-risk sites, and expanding inspection coverage of the global supply chain.